Large-vessel vasculitis (LVV) manifests as inflammation of the aorta and its major branches
and is the most common primary vasculitis in adults. LVV comprises two distinct conditions …

The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic
drugs (DMARDs) is an evolving area. A systematic review of Scopus, Web of Science …

Although outcomes in Takayasu arteritis (TAK) are improving, diagnosis is typically delayed
and significant arterial injury accrues. While wider use of non-invasive imaging is impacting …

Background Takayasu arteritis (TA) is a rare, systemic, inflammatory vasculitis of
granulomatous nature, and still of unknown etiology. It mainly involves the aorta and its …

Takayasu arteritis (TAK) is a challenging chronic, granulomatous, large-vessel systemic
vasculitis, mostly due to difficulties in early diagnosis and assessing actual disease activity …

Objective. Assessment of disease activity is one of the major difficulties in patients with
Takayasu arteritis (TA) during follow-up. To date, no biomarker is universally accepted to be …

Interleukin-6 inhibitors appear efficacious in the treatment of refractory cases of LVV;
however, utility in newly diagnosed immunosuppressive-naïve patients is less well …

Background Takayasu arteritis (TA) predisposes to the development of arterial stenoses and
aneurysms, and is associated with considerable morbidity and mortality amongst young …

Vascular surgery remains an important option in the management of Takayasu arteritis (TA).
Its use is predominantly confined to the treatment of symptomatic organ ischaemia or life …

Objective. To assess the efficacy of tocilizumab (TCZ) in patients with Takayasu arteritis (TA).
Methods. Multicentre open-label retrospective study. Results. Eight patients (all women) with …